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Allergic contact dermatitis can develop following repeated exposure to allergenic substances. To date,
hazard identiﬁcation is still based on animal studies as non-animal alternatives have not yet gained glo-
bal regulatory acceptance. Several non-animal methods addressing key-steps of the adverse outcome
pathway (OECD, 2012) will most likely be needed to fully address this effect. Among the initial cellular
events is the activation of keratinocytes and currently only one method, the KeratinoSens™, has been for-
mally validated to address this event. In this study, a further method, the LuSens assay, that uses a human
keratinocyte cell line harbouring a reporter gene construct composed of the antioxidant response ele-
ment (ARE) of the rat NADPH:quinone oxidoreductase 1 gene and the luciferase gene. The assay was val-
idated in house using a selection of 74 substances which included the LLNA performance standards. The
predictivity of the LuSens assay for skin sensitization hazard identiﬁcation was comparable to other non-
animal methods, in particular to the KeratinoSens™. When used as part of a testing battery based on the
OECD adverse outcome pathway for skin sensitization, a combination of the LuSens assay, the DPRA and a
dendritic cell line activation test attained predictivities similar to that of the LLNA.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-SA license
(http://creativecommons.org/licenses/by-nc-sa/3.0/).1. Introduction Currently, there is no non-animal alternative test method forIn a regulatory context, the sensitizing potential of substances is
generally evaluated using animal tests, such as the murine local
lymph node assay (LLNA; OECD TG 429) or the guinea pig-based
tests described in OECD TG 406 (OECD TG 406). As of March 11,
2013, the European Union imposed an animal testing ban on both
cosmetic products and their ingredients which is accompanied by a
concomitant marketing ban, if animal tests conducted after this
date for the purpose of the cosmetics legislation (EU, 2009).
In addition, under the European chemicals legislation REACH,
skin sensitization data for any substances registered under the
European Chemicals Legislation (REACH, EC 1907/2006) is manda-
tory, animal testing should only be performed only a last resort
(http://echa.europa.eu/documents/10162/13639/alternatives_test_
animals_2014_en.pdf).the endpoint of skin sensitization yet available that has gained full
regulatory acceptance. During the last decades, extensive work has
been conducted to develop in vitro assays able to replace current
animal test methods for the predictive identiﬁcation of skin sensi-
tizers (reviewed in Mehling et al., 2012). Given the complexity of
the sensitization pathway, a combination of tests will be needed
to achieve reliable predictions of the skin sensitization potential
of a substance.
In 2012 the OECD published the adverse outcome pathway
(AOP) for skin sensitization (OECD 2012a, 2012b, 2012c) in which
the key steps in the sensitization process are deﬁned. According to
the AOP, one of the early key events of the sensitization process is
the induction of cytoprotective gene pathways that occur within
keratinocytes (KCs) upon contact with a sensitizer. KCs are the
dominant cells in the epidermis and are among the ﬁrst cells to
come into contact with a sensitizer. In this context, various studies
have shown that the Nrf2-Keap1 pathway plays an important role
in skin sensitization (Ade et al., 2009; Natsch and Emter, 2008;
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scription factor nuclear factor erythroid 2 (Nrf2) is constitutively
expressed but is complexed and targeted for ubiquinylation in
the cytosol by the cytosensor protein Kelch-like ECH-associated
protein 1 (Keap1). In response to covalent modiﬁcation of the
highly reactive cysteine residues of Keap1 via stressors, Nrf2 is
released. Free Nrf2 translocates to the nucleus, where it heterodi-
merizes with other molecules (e.g., small Maf or Jun proteins). This
complex then binds to the so called ‘‘antioxidant response element
(ARE)’’ in the promoter region of several genes, including hmox1
and nqo1, subsequently initiating transcription of the downstream
genes (Ade et al., 2009). The Keap1 protein therefore constitutes an
intracellular sensor protein for electrophilic and oxidative stress.
Skin sensitizers are thought to directly or indirectly react with cys-
teine residues of Keap1, thereby enhancing Nrf2 release (Emter
et al., 2010; Motohashi and Yamamoto, 2004). The principle of this
pathway has been used to develop reporter cells lines including
AREc32; ARE-HepG2 (Emter et al., 2010; Simmons et al., 2011)
and KeratinoSens™ (Emter et al., 2010; Natsch and Emter 2008).
In light of the urgent need to evaluate non-animal approaches
capable of reliably identifying skin sensitization hazards thereby
providing the basis for classiﬁcation and labelling, the European
Union Reference Laboratory for Alternatives to Animal Testing
(EURL ECVAM) has recently published its strategy on skin sensiti-
zation (EURL ECVAM, 2013a) describing its plan for the next ﬁve
years towards achieving these goals: the two main points of focus
will be the development of integrated testing strategies (ITS) to be
used within integrated assessment and testing approaches (IATA)
for skin sensitization and the facilitation of global acceptance of
the new approaches for skin sensitization hazard identiﬁcation
(EURL ECVAM, 2013a). Currently, the assessment of the reliability
and reproducibility of several test methods for skin sensitization,
namely the Direct Peptide Reactivity Assay (DPRA), human cell line
activation test (h-CLAT), KeratinoSens™) under the formal valida-
tion process at ECVAM has progressed to an advanced stage. The
ECVAM Scientiﬁc Advisory Committee (ESAC) EURL ECVAM
recently issued their recommendations on the DPRA (EURL
ECVAM, 2013b) and KeratinoSens™ (EURL ECVAM, 2013c) and
the methods appear adequate to be considered for inclusion in
an ITS using test methods that address various key events of the
OECD skin sensitization AOP (EURL ECVAM, 2013a). A pragmatic
approach to assess the skin sensitization without the use of ani-
mals and using these nonanimal alternative test methods has pre-
viously been proposed and a very good accuracy using a
substantial number of substances was found (Bauch et al. 2012
(n = 54); Natsch et al., 2013 (n = 145)).
In this study, the development and performance of the LuSens
assay is described. The LuSens assay utilizes a similar principle as
the KeratinoSens™ assay: human keratinocytes harbouring the
luciferase reporter gene under the control of an antioxidant
response element (ARE) are used to assess the induction of the
cytoprotective responses elicited by the genes controlled by the
ARE. The luciferase activity is used as a measure for this response.
The individual results obtained with 74 substances are reported
and the predictivity when the results are used as part of an
in vitro test battery when assessing 50 and 53 substances in com-
parison to human and LLNA data, respectively.2. Materials and methods
2.1. Generation of a transgenic cell line for identiﬁcation of skin
sensitizers
A human keratinocyte cell line (provided by RWTH, Aachen,
Germany) was genetically modiﬁed at the Institute of Anatomyand Cell Biology of the RWTH, Aachen (laboratory of Wruck).
Brieﬂy, the modiﬁcation was achieved by transfection of the cells
with the pGL4.20 [luc2/Puro] vector (Promega, Germany) carrying
the regulatory antioxidant response element (ARE) upstream of the
luciferase gene (Luc2, Promega, Germany). The ARE itself was
derived from the NADPH:quinone oxidoreductase 1 gene from rat
(ggtaccagtctagagtcacagtgacttggcaaaatcgctagc) cloned using the
KpnI (GGTACC) and NheI (GCTAGC) sites of the multiple cloning
site. Transfection was performed with JetPrime™ transfection
reagent and according to manufacturer’s protocol (Polyplus-trans-
fection SA, USA). Apart from the transfection of the ARE-Luc2
sequence, no further modiﬁcations were performed to this cell line.
Two days after transfection, cells were cultured in selection media
containing different concentrations of puromycin (0.25; 0.5; 1.0
and 1.5 lg/mL). In parallel, non-transfected cells were also incu-
bated in the same selection media in order to determine the con-
centration of antibiotic needed to select transfected cells. From
these experiments it was found that 1 lg/mL was the optimal
puromycin concentration to obtain only cells expressing the resis-
tance marker and concomitantly the ARE-Luc2 construct. After clo-
nal selection, transfected cells were maintained in culture with
puromycin (0.45 lg/mL).
2.1.1. Cell maintenance
Cells were maintained in T75 ﬂasks (TPP, Switzerland) with
20 mL of growth media (DMEM with 10% FBS Superior, 1% penicil-
lin/streptomycin, and 0.005% puromycin, all components from Bio-
chrom (Germany)) except puromycin, which was obtained from
Sigma (Germany), at 37 C in a humidiﬁed atmosphere containing
5% CO2 to a conﬂuence of 80–90%. Cells were propagated twice a
week as follows; cells were trypsinized, seeded at a density of
0.4  106 cells in T75 culture ﬂasks containing 20 mL of culture
media. Cells were incubated at 37 C in a humidiﬁed atmosphere
containing 5% CO2.
2.1.2. Selection of stable cell clones
Follow antibiotic selection, clonal colony selection was per-
formed in order to obtain a cell population homogeneously
expressing luciferase. For this purpose, single cells were seeded
in individual wells of 96 well plates. 24 single colonies were iso-
lated, further propagated, aliquots frozen and the clones tested
for their proﬁciency to activate ARE-Luc2. Proﬁciency was evalu-
ated by measuring the relative increase in luciferase activity fol-
lowing exposure to two concentrations of ethylene glycol
dimethacrylate (EGDMA, 75 lM and 150 lM) at non-cytotoxic
concentrations. The viability of the cells was evaluated using the
MTT assay. Brieﬂy, for luminescence analysis, 200 lL of cell sus-
pension corresponding to 1  104 cells per well were seeded in
96 white ﬂat-bottom well plates and incubated for 24 h. All incu-
bation steps were carried out in a humidiﬁed atmosphere at
37 C and 5% CO2. After incubation, culture media was replaced
with 150 lL of fresh media, 50 lL of EGDMA stock solution was
added to a ﬁnal concentration of 75 lM or 150 lM and the cells
were incubated for 48 h. After treatment, cell culture media was
removed and cells were washed twice with 300 lL PBS (with
Ca2+/Mg2+). After washing, 100 lL PBS (Ca2+/Mg2+ free) and
100 lL Steady-Glo-Mix reagent (Promega, Germany) were added
to each well. Plates were gently shaken in the dark for 10 min and
luminescence measured using a luminometer (Perkin Elmer ‘‘Vic-
tor 3’’ 1420 Multilabel counter or GloMax, Promega). For analysis
of cell viability, 200 lL of cell suspension, corresponding to
1  104 cells per well, were seeded into clear 96 well plate and
incubated for 24 h. After 24 h, cell culture media was replaced by
180 lL of fresh media and 20 lL of MTT solution added to each
well. Plates were sealed with breathable tape and incubated for
2 h. After incubation, media and MTT solution were removed,
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for 5 min. Absorptions at 570 nm and at 690 nm were measured in
a spectrophotometer; the latter wavelength was used as reference.
2.2. Test substances
Table 1 summarizes 74 test substances and their following
properties; molecular weights, purities, supplier, CAS number,
chemical classes, proposed reaction mechanisms, information
about known pro- or prehapten properties, human literature data,
EC3 (%) value of LLNA data and the respective literature reference.
2.3. LuSens assay
The LuSens assay consists of a cytotoxicity range ﬁnding
experiment from which the concentrations to be used in the
main experiment are calculated. In the case no cytotoxicity is
observed the recommended maximum concentration to be tested
is 2000 lM.
2.3.1. Cytotoxicity range ﬁnder experiment
Cells were suspended in 9 mL of assay media (DMEM with 10%
FBS Superior, Biochrom) per T75 ﬂask and subsequently quantiﬁed
with a Casy cell counting system (Roche, Germany). For analysis of
cell viability, cells were seeded into clear ﬂat bottom 96 well plates
(TPP, Switzerland; 1  104 in 200 lL per well). Test substances
were dissolved in DMSO in a series of 1:2 dilutions starting at
2000 mM (100 stock solution). Substances were further diluted
(1:25) in medium to obtain 4 stock solution. Final DMSO concen-
trations in the assay did not exceed 1%. Treatment was performed
by applying 50 lL of the test substance to each well (ﬁnal volume:
200 lL) for 48 h. Each substance was tested at twelve concentra-
tions in triplicate. Assessment of cell viability was performed using
the MTT assay as mentioned above. From the range ﬁnding exper-
iments, the concentration in which cell viability corresponds to no
less than 75% (CV75) was calculated. The highest tested concentra-
tion in the main experiment was then 1.2 CV75 (or 2000 lM if no
cytoxicity was observed).
2.3.2. Main experiment for luciferase expression and cell viability
For analysis of luciferase expression, cells were seeded into
white ﬂat bottom 96 well plates (TPP, Switzerland; 1  104 in
200 lL per well). Test substances were dissolved in DMSO (100
stock solution) at concentrations according to the preliminary
cytotoxicity data. Substances were further diluted (1:25) in med-
ium to obtain 4 stock solution. Final DMSO concentration on
the cells did not exceed 1%. The highest tested concentration was
1.2 CV75. Treatment was performed by applying 50 lL of the test
substance dilution to each well (ﬁnal volume: 200 lL) for 48 h.
Each substance was tested at six concentrations in triplicate. If
the classiﬁcation in both tests differed, a third test was conducted.
After treatment, cell culture media was removed and cells were
washed twice with 300 lL PBS (with Ca2+/Mg2+). After washing,
100 lL PBS (Ca2+/Mg2+ free) were added to each well and also
100 lL Steady-Glo-Mix reagent (Promega, Germany). Plates were
gently shaken in the dark for 10 min and luminescence then mea-
sured using a Perkin Elmer ‘‘Victor 3’’ 1420 Multilabel counter. For
analysis of cell viability, cells were seeded in clear ﬂat bottom 96
well plates (TPP, Switzerland; 1  104 in 200 lL per well). Test sub-
stances were dissolved in DMSO (100 stock solution). Substances
were further diluted (1:25) in medium to obtain 4 stock solution.
Final DMSO concentration on the cells did not exceed 1%. Treat-
ment was performed by applying 50 lL of the test substance dilu-
tion to each well (ﬁnal volume: 200 lL) for 48 h. Each substance
was tested in six concentrations (each concentration in triplicate).
In addition, the assay was performed in at least 2 independentexperiments. Concentrations were chosen according to preliminary
MTT cytotoxicity assays. Assessment of viable cells was also per-
formed by via MTT cytotoxicity assays. In parallel to the test sub-
stances, a positive control (EGDMA, 120 or 150 lM) was also
tested in all cases and in most cases a negative control was also
included (lactic acid (LA), 5000 lM).
2.3.3. Acceptance criteria and prediction model
For acceptance of the assay, at least 3 tested concentrations
with a viability above or equal to 70% must be available. The posi-
tive control, EGDMA, must lead to a 2.5 fold or higher induction of
luciferase in comparison to the vehicle control (VC). The luciferase
activity induced by lactic acid must be below 1.5 fold of the VC and
at viabilities above 70%. Moreover, average standard deviation of
the VC should not exceed 20%.
The fold induction (FI) of the luminescent signal was calculated
by dividing the relative luminescence units (RLU) of the treated
cells (TC) by the RLU of VC cells using following equation: FI = (RLU
TC)/(RLU VC). A test compound was considered to have ARE acti-
vating potential (sensitizing potential) when the luciferase induc-
tion was statistically signiﬁcant above or equal to 1.5 fold
compared to the VC in more than 2 consecutive non-cytotoxic
tested concentrations (according to the t-test) whereby three con-
centrations must be non-cytotoxic. A test compound is considered
to not to have sensitizing potential if the above criteria for an ARE
activating potential were not met.
In order to come to a conclusion on the ARE activating potential
of a substance, one complete experiment needs to be conducted. A
complete experiment consists of two valid independent repeti-
tions. If both repetitions come to the same result (i.e., either being
negative or being positive) no further testing is required. In case
that the ﬁrst two repetitions give discordant results (i.e., one is
negative and the other is positive), a third independent repetition
needs to be conducted to complete the experiment.
The ARE activating potential of a test substance is determined
by the result of the majority of the repetitions of an experiment.
If two of two or two of three repetitions are negative/positive,
the substance is considered to be a nonsensitizer/sensitizer.
In addition, in accordance to the above prediction models, the
predictivity of LuSens was determined according to Cooper statis-
tics (Cooper et al., 1979) using the following to assess sensitivity,
speciﬁcity, positive and negative predictive value and accuracy:
sensitivity: (TP/[TP + FN]  100); speciﬁcity: (TN/[TN + FP]  100);
positive predictivity: (TP/[TP + FP]  100); negative predictivity:
(TN/[TN + FN]  100); accuracy: (TP + TN/[TN + TP + FP + FN] 
100) with FN being the number of false negative calls, FP the num-
ber of the false positive calls, TN the number of the true negative
calls and TP the number of the true positive calls.3. Results
Herein, we report on the development of the LuSens assay,
which utilizes a reporter gene cell line based on the ARE pathway
activation to assess the skin sensitization potential of a chemical.
Cells transfected with the pGL4.20-ARE-Luc2 construct were
selected via resistance to the antibiotic puromycin. From these
experiments, a population expressing luciferase under the control
of ARE was obtained and the clone with the most suitable charac-
teristics selected.
3.1. Generation of cell line with ARE-dependent reporter gene function
Following transfection with the reporter gene construct, a clo-
nal selection was performed in order to generate a stably transfec-
ted cell line which expresses homogeneous levels of luciferase and
Table 1
Overview of the test substances used for the validation of the LuSens assay. Information about the sensitization potential of the test substances in mice (LLNA) and humans is indicated by ‘‘+’’ (sensitizing) and ‘‘’’ (not sensitizing); ‘‘NC’’
indicates not calculated.
Chemical information Human data LLNA data
No. Substance Molecular
weight [g/
mol]
Purity Supplier CAS # Chemical class Mechanism Literature Pro/
prehapten
Human Literature EC3
(%)
Potency
class
LLNA Literature
1 Oxazolone 217.2 98% Sigma 15646-
46-5
Oxazole Acylating
agent
Patlewicz
et al. (2008)
+ Basketter et al.
(1999)
0.003 Extreme + Kimber
et al. (2003)
2 MCI/MI Mixture 99% Sigma–
Aldrich
26742-
55-4/
2682-
20-4
Aromatic halide Michael
acceptor
Patlewicz
et al. (2008)
+ Basketter et al.
(1999)
0.009 Extreme + Kimber
et al. (2003)
3 p-Benzoquinone 108.1 99% Sigma–
Aldrich
106-
51-4
quinone Michael
acceptor
Patlewicz
et al. (2008)
+ Basketter et al.
(1999)
0.0099 Extreme + Gerberick
et al. (2005)
4 1-Chloro-2,4-
dinitrobenzene
202.6 95% Aldrich 97-00-
7
Nitroaromatic,
aromatic halide
SNAr agent Patlewicz
et al. (2008)
+ Basketter et al.
(1999)
0.049 Extreme + Kimber
et al. (2003)
5 Potassium
dichromate
294.2 P99.5% Sigma–
Aldrich
7778-
50-9
Inorganic salt SN1 agent Roberts et al.
(2007)
+ Basketter et al.
(2014)
0.08 Extreme + Basketter
et al. (1994)
6 Metol 344.4 P98.0% Fluka 55-55-
0
Aromatic alcohol,
aromatic amine
Quinone
precursor
Aptula et al.
(2009),
Roberts et al.
(2007)
Pre/pro-
MA
+ Basketter et al.
(2014)
0.8 Strong + Basketter
et al. (2014)
7 Glutaraldehyde 100.1 25% in
H2O
Sigma-
Aldrich
111-
30-8
Ketone Schiff base Aptula and
Roberts
(2006)
+ Basketter et al.
(2014)
0.1 Strong + Basketter
et al. (2014)
8 4-Phenylenediamine 108.1 97% Sigma 106-
50-3
Aromatic amine Quinone
precursor
Patlewicz
et al. (2008)
Pre/pro-
MA
+ Basketter et al.
(1999)
0.16 Strong + Gerberick
et al. (2005)
9 Propyl gallate 212.2 99% Fluka 121-
79-9
Polysubstituted
aromatic alcohol
Quinone
precursor
Aptula et al.
(2009)
Pre/pro-
MA
+ Basketter et al.
(1999)
0.32 Strong + Natsch and
Emter
(2008)
10 2,4,6-Trinitro
benzenesulfonic acid
293.2 98% Sigma 2508-
19-2
Nitroaromatic SNAr agent Roberts et al.
(2007)
No suitable data
available
0.36 Strong + Robinson
et al. (1989)
11 Phthalic anhydride 148.1 5% Fluka 85-44-
9
Aromatic carboxylic
acid anhydride
Acylating
agent
Aptula and
Roberts
(2006)
+ Basketter et al.
(1999)
0.36 Strong + Kimber
et al. (2003)
12 Formaldehyde > 36%
(1% in DMSO)
30.0 99% Sigma 50-00-
0
Aliphatic aldehyde Schiff base Patlewicz
et al. (2008)
+ Basketter et al.
(1999)
0.61 Strong + Gerberick
et al. (2005)
13 Methyldibromo
glutaronitrile
265.9 98% Aldrich 35691-
65-7
Nitrile/alkyl halide SN2 agent Author’s data + SCCP (2005) 0.9 Strong + Basketter
et al. (2008)
14 Glyoxal solution 58.0 40%
in H2O
Sigma 107-
22-2
Aliphatic aldehyde Schiff base Roberts et al.
(2007)
+ Basketter et al.
(2014)
1.4 Moderate + Basketter
et al. (2014)
15 Isoeugenol 164.2 99% Sigma-
Aldrich
97-54-
1
Phenylpropanoid Quinone
precursor
Aptula and
Roberts
(2006)
Pre/pro-
MA
+ Basketter et al.
(1999)
1.5 Moderate + Kimber
et al. (2003)
16 Diethyl maleate 172.2 99% Sigma 141-
05-9
a, ß-unsaturated
ester
Michael
acceptor
Patlewicz
et al. (2008)
+ Ryan et al. (2000) 2.1 Moderate + Kimber
et al. (2003)
17 Ethylene diamine 60.1 99% Sigma 107-
15-3
Aliphatic amine Schiff base Patlewicz
et al. (2008)
Pre/pro-
SB
+ Basketter et al.
(1999)
2.2 Moderate + Gerberick
et al. (2005)
18 Benzylidene acetone 146.2 99% Aldrich 122-
57-6
a, ß-unsaturated
ketone
Michael
acceptor
Aptula and
Roberts
(2006)
+ Schneider and Akkan
(2004)
3.7 Moderate + Gerberick
et al. (2005)
(continued on next page)
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Table 1 (continued)
Chemical information Human data LLNA data
No. Substance Molecular
weight [g/
mol]
Purity Supplier CAS # Chemical class Mechanism Literature Pro/
prehapten
Human Literature EC3
(%)
Potency
class
LLNA Literature
19 Cinnamic aldehyde 132.2 >95% Aldrich 104-
55-2
a, ß-unsaturated
aldehyde
Michael
acceptor
Roberts et al.
(2007)
+ Basketter et al.
(2014)
3 Moderate + Basketter
et al. (2014)
20 Cobalt chloride 129.8 98% Aldrich 7791-
13-1
Inorganic salt Coordination
bonds
Author’s data + Basketter et al.
(1999)
0.57 Strong + OECD
(2010)
21 Thiram 240.4 97% Aldrich 137-
26-8
Dithiocarbamate SN2 agent Roberts et al.
(2007)
+ Basketter et al.
(2014)
5.2 Moderate + Basketter
et al. (2014)
22 2-Phenyl
propionaldehyde
134.2 99% Sigma–
Aldrich
93-53-
8
Aldehyde Schiff base Roberts et al.
(2007)
+ Schneider and Akkan
(2004)
5.9 Moderate + Natsch and
Emter
(2008)
23 Resorcinol 110.1 99% Sigma–
Aldrich
108-
46-3
Aromatic alcohol Quinone
precursor
Aptula et al.
(2009)
Pre/pro-
MA
 Aptula et al. (2009) 6.3 Moderate + Basketter
et al. (2014)
24 a-Hexyl-cinnamic
aldehyde
216.3 98% Aldrich 101-
86-0
Aldehyde Michael
acceptor
Patlewicz
et al. (2008)
+ Basketter et al.
(1999)
8 Moderate + Kimber
et al. (2003)
25 Tartaric acid 150.1 98% Aldrich 133-
37-9
Aliphatic carboxylic
acid/glycol
Non-binding Patlewicz
et al. (2008)
- Basketter et al.
(1999)
8.7 Moderate + Gerberick
et al. (2005)
26 2-Mercapto
benzothiazole
167.2 99.50% Sigma 149-
30-4
Thiazole/
heterocyclic
SN2 agent Roberts et al.
(2007)
+ Basketter et al.
(1999)
9.7 Moderate + Kimber
et al. (2003)
27 2.3-Butanedione 86.1 10.15% Sigma 431-
03-8
(1.2-di-) ketone Schiff base Patlewicz
et al. (2008)
No suitable data
available
11 Weak + Gerberick
et al. (2005)
28 Citral 152.2 98.10% BASF 5392-
40-5
Aldehyde/
terpenoids
Schiff base Patlewicz
et al. (2008)
+ Basketter et al.
(1999)
13 Weak + Kimber
et al. (2003)
29 Eugenol 164.2 90% Fluka 97-53-
0
Phenylpropanoid Quinone
precursor
Patlewicz
et al. (2008)
Pre/pro-
MA
+ Basketter et al.
(1999)
13 Weak + Gerberick
et al. (2005)
30 Farnesal 220.4 >99.5% Sigma 19317-
11-4
Sesquiterpenalkohol Schiff base Patlewicz
et al. (2008)
No suitable literature 13 Weak + Gerberick
et al. (2005)
31 Sodium lauryl sulfate 288.4 99% Sigma–
Aldrich
151-
21-3
Alkyl sulfate Non-binding Patlewicz
et al. (2008)
- Basketter et al.
(1999)
14 Weak + Gerberick
et al. (2005)
32 4-Allylanisole 148.2 95% Aldrich 140-
67-0
Aromatic alkyl
ether/
phenylpropanoid
Michael
acceptor
Patlewicz
et al. (2008)
Pro No suitable data
available
18 Weak + Gerberick
et al. (2005)
33 Hydroxycitronellal 172.3 99% Sigma 107-
75-5
Terpene aldehyde Schiff base Patlewicz
et al. (2008)
+ Basketter et al.
(1999)
20 Weak + Kimber
et al. (2003)
34 Phenyl benzoate 198.2 99.4% Fluka 93-99-
2
Benzoate (ester) Acylating
agent
Patlewicz
et al. (2008)
+ OECD (2010) 20 Weak + Gerberick
et al. (2005)
35 Cinnamic alcohol 134.2 97% Alfa
Aesar
104-
54-1
a, ß-unsaturated
alcohol
Michael
acceptor
Patlewicz
et al. (2008)
Pro + OECD (2010) 21 Weak + Gerberick
et al. (2005)
36 Imidazolidinyl urea 388.3 99% Sigma 39236-
46-9
Imidazoline Acylating
agent
Patlewicz
et al. (2008)
+ Basketter et al.
(1999)
24 Weak + Gerberick
et al. (2005)
37 Undecylenic acid 184.3 >95% Fluka 112-
38-9
Carboxylic acid Non-binding Author’s data + Kreiling et al. (2008) 25 Weak + Kreiling
et al. (2008)
38 Ethylene glycol
dimethacrylate
198.2 99% Aldrich 97-90-
5
a, ß-unsaturated
ester
Michael
acceptor
Patlewicz
et al. (2008)
+ Basketter et al.
(1999)
35 Weak + Kimber
et al. (2003)
39 Pyridin 79.1 99% Sigma 110-
86-1
Aromatic
heterocyclic
Non-binding Patlewicz
et al. (2008)
 Basketter et al.
(1999)
71.2 Weak + Gerberick
et al. (2005)
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40 Aniline 93.1 99% Sigma 62-53-
3
Aromatic amine Non-binding Roberts et al.
(2007)
+ Basketter et al.
(1999)
89 Weak + Gerberick
et al. (2005)
41 Methyl methacrylate 100.1 99% SAFC 80-62-
6
a, ß-unsaturated
ester
Michael
acceptor
Author’s data + OECD (2010) 90 Weak + OECD
(2010)
42 4-Nitrobenzyl
bromide
216.0 99% Aldrich 100-
11-8
Benzyl halide SN2 agent Roberts et al.
(2007)
No suitable data
available
n.d. n.d. + NIH (1999)
43 Butyl paraben 194.2 >99.5% Aldrich 94-26-
8
Aromatic ester Non-binding Roberts et al.
(2007)
+ Cosmetic review
expert panel (2008)
n.d. n.d. + Cosmetic
review
expert
panel
(2008)
44 Methyl paraben 152.2 P98.0% Sigma 99-76-
3
Aromatic ester Non-binding Roberts et al.
(2007)
+ Cosmetic review
expert panel (2008)
n.d. n.d. + Cosmetic
review
expert
panel
(2008)
45 Sorbic acid 112.1 99.7% Fluka 110-
44-1
a, ß-unsaturated
acid
Non-binding Author’s data + Menné et al. (2009) n.d. Weak + Patrizi et al.
(1999)
46 Benzoylperoxide 242.2 75% Aldrich 94-36-
0
Peroxy ester Acylating
agent
Author’s data + Haustein et al.
(1985), Schneider
and Akkan (2004)
41 Weak + Schneider
and Akkan
(2004)
47 Butyl glycidyl ether 130.2 95% Aldrich 2426-
08-6
Epoxide SN2 agent Roberts et al.
(2007)
+ Schneider and Akkan
(2004)
28 Weak + Basketter
et al. (1996)
48 Ethylparaben 166.2 na Fluka 120-
47-8
Aromatic ester Non-binding Roberts et al.
(2007)
+ Cosmetic review
expert panel (2008)
n.d. n.d. + Marzulli
and
Maibach
(1974)
49 2-Bromo-2-nitro-
1.3-propanediol
200.0 98% Aldrich 52-51-
7
Halogenated nitro
alcohol
SN1/2 agent Author’s data + Hahn et al. (2005),
Marzulli and
Maibach (1974),
Maibach (1977)
No suitable
data
available
50 Xylene 106.2 95% Aldrich 1330-
20-7
Aromatic
hydrocarbon
Non-binding Author’s data  Basketter et al.
(1999)
95.8 Weak  OECD
(2010)
51 Glycerol 92.1 90% Fluka 56-81-
5
Aliphatic alcohol Non-binding Patlewicz
et al. (2008)
– Basketter et al.
(1999)
100.02 Non  Natsch and
Emter
(2008)
52 1.2-Propanediol 76.1 99.5% Supelco 57-55-
6
Aliphatic alcohol Non-binding Patlewicz
et al. (2008)
 Basketter et al.
(1999)
100.11 Non  Natsch and
Emter
(2008)
53 4-Hydroxybenzoic
acid
138.1 99% Aldrich 99-96-
7
Phenolic acid Non-binding Patlewicz
et al. (2008)
 Basketter et al.
(1999)
NC Non  Gerberick
et al. (2005)
54 4-Methoxy
acetophenone
150.2 99% Sigma–
Aldrich
100-
06-1
Ketone ether Non-binding Patlewicz
et al. (2008)
 Gerberick et al.
(2001)
NC Non  Gerberick
et al. (2005)
55 6-Methylcoumarin 149.6 99% Sigma 92-48-
8
a, ß-unsaturated
ester/lactone
Michael
acceptor
Patlewicz
et al. (2008)
 Basketter et al.
(1999)
NC Non  Gerberick
et al. (2005)
56 Chlorobenzene 112.6 98.5% Fluka 108-
90-7
Aromatic halide Non-binding Patlewicz
et al. (2008)
 OECD (2010) NC Non  Gerberick
et al. (2005)
57 DL-lactic acid 90.1 99.80% Sigma 50-21-
5
Organic acid,
aliphatic alcohol
Non-binding Patlewicz
et al. (2008)
 Basketter et al.
(1999)
NC Non  Gerberick
et al. (2005)
58 Fumaric acid 116.1 99.70% Sigma 110-
17-8
Dicarbonic acid Non-binding Author’s data  Hansson and
Thoerneby-
Andersson (2003)
NC Non  Kreiling
et al. (2008)
(continued on next page)
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Table 1 (continued)
Chemical information Human data LLNA data
No. Substance Molecular
weight [g/
mol]
Purity Supplier CAS # Chemical class Mechanism Literature Pro/
prehapten
Human Literature EC3
(%)
Potency
class
LLNA Literature
59 Glucose 180.2 98% Aldrich 55-99-
7
Carbohydrate Non-binding Author’s data  Bauch et al. (2012)  Bauch et al.
(2012)
60 Isopropanol 60.1 99% Fluka 67-63-
0
Aliphatic alcohol Non-binding Patlewicz
et al. (2008)
 Basketter et al.
(1999)
NC Non  Gerberick
et al. (2005)
61 Methyl salicylate 152.1 99% Aldrich 119-
36-8
Aromatic ester Non-Binding Patlewicz
et al. (2008)
 Basketter et al.
(1999)
NC Non  Gerberick
et al. (2005)
62 n-Butanol 74.1 99% Sigma–
Aldrich
71-36-
3
Aliphatic alcohol Non-binding Patlewicz
et al. (2008)
– Ryan et al. (2000) NC Non  Gerberick
et al. (2005)
63 n-Hexane 86.2 99% Sigma 110-
54-3
Hydro carbon Non-binding Patlewicz
et al. (2008)
 Basketter et al.
(1999)
NC Non  Gerberick
et al. (2005)
64 Nickel chloride 129.6 98.5% Fluka 7718-
54-9
Inorganic salt Coordination
bonds
Author’s data + Basketter et al.
(1999)
NC Non  OECD
(2010)
65 p-Aminobenzoic acid 137.1 98% Fluka 150-
13-0
Aromatic amine
organic acid
Non-binding Aptula and
Roberts
(2006)
 Basketter et al.
(1999)
NC Non  Basketter
et al. (2008)
66 Propyl paraben 180.2 99.80% Sigma 94-13-
3
Aromatic ester Non-binding Roberts et al.
(2007)
 Basketter et al.
(1999)
NC Non  Gerberick
et al. (2005)
67 Salicylic acid 138.1 98% Sigma-
Aldrich
69-72-
7
Aromatic alcohol,
organic acid
Non-binding Patlewicz
et al. (2008)
 Basketter et al.
(1999)
NC Non  Gerberick
et al. (2005)
68 Sulfanilamide 172.2 99% Sigma 63-74-
1
Aromatic sulfon,
aromatic amine
Non-binding Patlewicz
et al. (2008)
 Basketter et al.
(1999)
NC Non  Gerberick
et al. (2005)
69 Vanillin 152.2 98.5% T.J.
Baker
121-
33-5
Phenolic aldehyde Non-binding Patlewicz
et al. 2008
 Uter et al. (2010) NC Non  Gerberick
et al. (2005)
70 Hexadecyltrimethyl
ammonium bromide
364.45 99% Sigma 57-09-
0
Aliphatic cation
(quaternary
ammonium)
Non-binding Author’s data  Andersen and
Frankild (1997)
No suitable
data
available
71 Tween 80 1310.0 P58.0% Sigma–
Aldrich
9005-
65-6
Polyfunctional ester Non-binding Author’s data  Basketter et al.
(2014)
NC Non  Emter et al.
(2010)
72 Diethyl phthalate 222.2 99.5% Aldrich 84-66-
2
Aromatic ester Non-binding Roberts et al.
(2007)
 Schneider and Akkan
(2004)
NC Non  Ryan et al.
(2000)
73 Sodium benzoate 144.1 99.5% Aldrich 532-
32-1
Organic carboxylate Non-binding Author’s data  SCCP (2005) NC Non  SCCP
(2005)
74 Benzyl alcohol 108.1 99.80% Sigma–
Aldrich
100-
51-6
Benzyl alcohol Non-binding Author’s data + Schnuch et al. (1998) NC Non  RIFM
database
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T. Ramirez et al. / Toxicology in Vitro 28 (2014) 1482–1497 1489the optimal signal to noise ratio of luciferase induction. Single cell
clones (n = 24) were selected and propagated. The relative basal
expression level of these clones was compared (Fig. 1): 17 out of
24 colonies expressed basal luciferase levels which changed only
marginally to 0.5–1 fold when treated with solvent only (VC). 5
out of 24 colonies expressed luciferase levels between >1 and 1.5
fold compared to VC, one clone expressed basal luciferase levels
below 0.5 fold compared to VC (Fig. 1), and only one clone (clone
18) did not show any luciferase expression. To determine the range
of induction of luciferase following exposure to sensitizing sub-
stances, the clones were exposed to a weak sensitizer, EGDMA, at
two concentrations (75 lM and 150 lM). As illustrated in Fig. 2,
the clones exhibited a concentration dependent induction of lucif-
erase. The lower concentration of EGDMA, 75 lM, induced lucifer-
ase expression from 1.5 to 4.6 fold in 22 of 24 clones; an induction
of only 1.1 fold was observed for one clone (24). In addition to
luciferase induction, viability was also measured: in 21 of 24
clones EGDMA did not induce cytotoxicity above 20% and in only
two clones (1 and 13) the viability was below 80% when treated
with 75 lM EGDMA (Fig. 2). Luciferase induction was higher in
cells treated with 150 lM EGDMA, ranging from 2 to 9 fold in 22Fig. 1. (A) Basal luciferase activity of 23 clones of LuSens cells (grey bars), the expressio
vehicle control (VC, DMSO 1%). Data for clone 18 are not displayed since this clone did
without DMSO (blue diamonds) was compared to the viability of each clone treated wit
dimethacrylate (EGDMA, 75 lM white bars; 150 lM grey bars, the black bars correspo
Viability relative to VC is also illustrated per clone (black lines). (For interpretation of the
this article.)of 24 clones; one clone (clone 24) exhibited an induction below
2 fold. Viability was reduced below 70% in three clones (1, 5 and
9), while the rest of the clones retained good viability. Based on
these experiments clone 16 was selected as the best clone because
of its low basal activity and its good capacity to be activated when
exposed to EGDMA and was selected to further develop the LuSens
assay.
The cytogenetic analysis of clone 16 was also performed and the
results were consistent with a cell-line of human origin, presenting
a hypertriploid karyotype with an average number of 77 chromo-
somes (modal range from 74 to 80) and 6 marker chromosomes
(M1–M6), of which 3 showed 2 copies each. In addition, genomic
DNA of this clone was isolated for veriﬁcation of the presence of
the ARE sequence. Sequencing demonstrated that the sequence of
the ARE of the reporter gene construct was present without any
modiﬁcation (data not shown). When a Blast search of the ARE
sequence using whole genomic DNA sequences from the NCBI gen-
ome database (http://www.ncbi.nlm.nih.gov/genome) was con-
ducted, the sequence from LuSens clone 16, provided a 100%
identity with the NAD(P)H dehydrogenase [quinone] 1 gene
(Nqo1) sequence of Rattus norvegicus strain BN; Sprague-Dawleyn of single clones were compared to the expression of each clone treated with the
not show detectable basal luciferase activity. In addition, the viability of the clones
h VC. (B) Effect of increasing concentrations of the weak sensitizer, ethylene glycol
nd to VC) towards the luciferase expression of 23 selected clones of LuSens cells.
references to color in this ﬁgure legend, the reader is referred to the web version of
Fig. 2. Exemplary performance of LuSens cells clone 16 towards skin sensitizers and non-sensitizers. Effect of increasing concentrations of EGDMA (A), cinnamyl alcohol (B),
sulfanilamide (C) and vanillin (D) on the luciferase expression (bars) and viability (green squares) of LuSens cells clone 16, illustrated are results of three independent
experiments. After exposure with skin sensitizers (A and B) an increase in the luciferase expression above the 1.5 fold threshold is observed in a dose dependent manner in
non-cytotoxic concentrations. Contrastingly, no luciferase induction is observed above the 1.5 fold threshold, even at concentrations close to cell toxicity, indicating no
activation of LuSens cells.
1490 T. Ramirez et al. / Toxicology in Vitro 28 (2014) 1482–1497(Sequence ID: ref AC_000087.1). It is important to highlight that
ARE consensus sequence, responsible for ARE functionality among
species (i.e., human, mouse, rat), TMAnnRTGAYnnnGCRwww
(where M = A or C, R = A or G, Y = C or T, W = A or T, S = G or C)
(Wasserman and Fahl, 1997) is present in the rat ARE sequence
found in LuSens cells.
3.2. Assay development and predictivity according to Cooper statistics
In order to determine the predictive capacity of the LuSens
assay, 74 test compounds with animal and/or human sensitization
data available (Table 1) were tested in at least two independent
experiments in order to compare to human and LLNA data from
the literature. The LuSens assay correctly predicted 57 of 69 or
53 of 74 substances when compared to human or LLNA data,
respectively. When compared to human data, seven substances
were incorrectly rated to be negative: aniline, ethylene diamine,
Luperox A75 (benzoyl peroxide), nickel chloride, phenyl benzoate,
phthalic anhydride and propyl gallate. Five substances were incor-
rectly rated as positive when compared to human data: 4
methoxyacetophenone, 6-methylcoumarin, methyl salicylate, pro-
pyl-4-hydroxybenzoate, and tween 80. When compared to LLNA
data, twelve substances would be incorrectly rated to be negative:
4-allylanisole, aniline, ethylene diamine, farnesal, hexadecyltrime-
thylammonium bromide, phthalic anhydride, phenyl benzoate,
propyl gallate, pyridin, sodium lauryl sulfate (SDS), resorcinol, tar-
taric acid and xylene. It should be noted that hexadecyltrimethy-
lammonium bromide, pyridine, SDS, tartaric acid, resorcinol and
xylene yield false positive results in the LLNA when compared to
human data. Eight substances would be incorrectly rated to be
positive when compared to LLNA data: 4-methoxyacetophenone,
6-methlycoumarin, benzyl alcohol, methyl salicylate, propyl 4-
hydroxybenzoate, and tween 80 (Table 2). For the assessment of
the predictive capacity of the LuSens assay, the data obtained from
the in vitro assay were compared to human or LLNA data from the
literature using cooper statistics (Table 3). From this analysis the
following predictivity values were calculated: Sensitivity of 83%or 73%, speciﬁcity of 81% or 74% and an overall accuracy of 83%
or 74% when compared to human or LLNA data, respectively.
3.3. Intralaboratory reproducibility
The intralaboratory reproducibility of the LuSens assay was
assessed based on the concordance of the classiﬁcation of indepen-
dent valid runs testing the same substance. All valid runs, namely
those that adhered to the acceptance criteria, were considered
even if an overall conclusion was already reached after two runs.
From this analysis it was found that the assessment of 69 of 74
compounds was consistently reproducible (93%) and the assess-
ment of 5 compounds, 4-allylanisole, benzyl alcohol, glyoxal solu-
tion, Luperox A75 and n-butanol, were not reproducible along the
independent runs (Table 2).
3.4. Comparison of the LuSens and KeratinoSens™ assays
In general KeratinoSens™ and LuSens assays possess similar
capacity to predict sensitizers. In KeratinoSens™ the luciferase
gene is regulated by the ARE-element of the human aldoketoreduc-
tase (AKR1C2), whereas in LuSens it is under the control of ARE ele-
ment from the rat NADPH:quinone oxidoreductase (nqo1). Another
major difference between both assays is that LuSens uses a cyto-
toxicity range ﬁnder experiment to select 6 testing concentration
to analyze the luciferase activity, KeratinoSens™ in contrast uses
a range of 12 ﬁxed concentrations from 1 to 200 lM. In addition,
while LuSens plate set up uses all replicates for all concentrations
in one plate in order to avoid potential plate differences effect on
the replicates, KeratinoSens™ distribute the three replicates of
each testing concentrations in 3 independent plates. The last major
difference will be validity controls of both assays, for LuSens a neg-
ative and positive control is used, DL-Lactic acid and EGDMA,
respectively, while KeratinoSens™ uses as positive control cin-
namic aldehyde. The analysis of same data set in comparison to
the data reported for KeratinoSens™ (Natsch et al., 2013; Natsch
et al., 2011; Bauch et al., 2012) indicates a good concordance of
Table 2
Summary results of the LuSens assay. Depicted are the Imax (maximal induction), the concentration at which the 1.5 fold and 2 fold induction was observed (lM), the number of
experiments showing a statistical signiﬁcant 1.5 fold and 2 fold induction, the concentration (lM) at which 50% cytotoxicity was induced. Generally no cytotoxicity was observed
at the 1.5 fold induction. In addition, the reproducibility is indicated by ‘‘R’’ for reproducible and ‘‘NR’’ for not reproducible. The results obtained from the LuSens assay were
compared to those reported on the literature for KeratinoSens™ assay. Where results from both assays were concordant, a match is indicated as ‘‘M’’, in contrast, when data from
both assays were discordant, a mismatch is indicated by ‘‘MM’’. When literature data from KeratinoSens™ was inconclusive (different results reported in the literature), no ‘‘M’’ or
‘‘MM’’ could be assessed, then this was indicated as ‘‘?’’. Where no KeratinoSens™ data were available, no comparison was made; indicated by ‘‘ND’’.
Test substance Imax
(fold)
Concentration
(lM) for 1.5
fold induction
Number
of EC1.5
positives
Concentration
(lM) for 2 fold
induction
Number
of EC2.0
positives
Concentration
(lM) causing
50%
cytotoxicity
LuSens
prediction
Reproducibility Comparison
with
KeratinoSens™
References
Oxazolone 7.49 <743.47 2 of 2 <743.47 2 of 2 >1850 + R M Natsch et al.
(2013)
MCI/MI 6.78 <4.6 3 of 3 <4.6 3 of 3 >900 + R M Natsch et al.
(2013)
p-Benzoquinone 2.58 9.69 2 of 2 <11.11 2 of 2 >16 + R M Natsch et al.
(2013)
1-Chloro-2,4-dinitro benzene 3.34 3.23 2 of 4 3.65 2 of 4 >5 + NR M Natsch et al.
(2013)
Potassium dichromate 2.95 0.82 2 of 2 1.19 2 of 2 >1.56 + R M Natsch et al.
(2013)
Metol 7.82 <10.99 4 of 4 <10.99 4 of 4 >27.35 + R M Natsch et al.
(2013)
Glutaraldehyde 5.99 <45.05 2 of 2 45.05 2 of 2 104.24 + R M Natsch et al.
(2013)
4-Phenylenediamine 11.44 <53.05 4 of 4 <53.05 4 of 4 >132 + R M Natsch et al.
(2013)
Propyl gallate 0.89 >140 0 of 2 >140 0 of 2 >140  R MM Natsch et al.
(2013)
Pricrysulfonic acid 5.94 <964.51 2 of 2 <964.51 2 of 2 >2400 + R ND
Phthalic anhydride 0.33 >2400 0 of 2 >2400 0 of 2 >2400  R M Natsch et al.
(2013)
Formaldehyde 3.99 184.38 3 of 3 214.28 3 of 3 >288 + NR M Natsch et al.
(2013)
Methyldibromo glutaronitrile 2.71 <16.08 3 of 3 18.98 2 of 3 >34.72 + R M Natsch et al.
(2013)
Glyoxal solution 4.64 <180.84 2 of 3 278.47 1 of 3 >450 + NR M Natsch et al.
(2013)
Isoeugenol 25.41 <120.56 3 of 3 <120.56 3 of 3 >300 + R M Natsch et al.
(2013)
Diethyl maleate 13.83 <24.11 2 of 2 <24.11 2 of 2 >60 + R M Natsch et al.
(2013)
Ethylene diamine 1.12 >750 0 of 2 >750 0 of 2 >750  R MM Natsch et al.
(2013)
Benzylidene acetone 21.81 <10.05 2 of 2 <10.05 2 of 2 >25 + R M Natsch et al.
(2013)
Cinnamic aldehyde 23.25 <44.21 3 of 3 <44.21 3 of 3 >110 + R M Natsch et al.
(2013)
Cobalt chloride 7.48 <241.13 3 of 3 <241.13 3 of 3 >600 + R M Natsch et al.
(2013)
Thiram 5.29 <20.82 4 of 4 <20.82 4 of 4 49.50 + R ND
2-Phenyl propionaldehyde 3.45 48.23 4 of 4 70.35 4 of 4 112.03 + R M Natsch et al.
(2013)
Resorcinol 0.58 >920.74 0 of 4 >920.74 0 of 4 >1104.89  R M Natsch et al.
(2013)
a-Hexyl-cinnamic aldehyde 3.30 14.53 2 of 2 18.99 2 of 2 29.56 + R ? Natsch et al.
(2013), Bauch
et al. (2012)
Tartaric acid 1.28 >2400 0 of 4 >2400 0 of 4 >2400  R ? Natsch et al.
(2013), Bauch
et al. (2012)
2-Mercapto benzothiazole 23.48 <361.69 3 of 3 <361.69 3 of 3 >900 + R M Natsch et al.
(2013)
2.3-Butanedione 8.30 <160.75 2 of 2 189.50 2 of 2 >400 + R M Nat sch et al.
(2013)
Citral 32.32 <48.23 3 of 3 <48.23 3 of 3 >120 + R M Natsch et al.
(2013)
Eugenol 5.49 <241.13 4 of 4 <241.13 4 of 4 >600 + R ? Natsch et al.
(2013), Bauch
et al. (2012)
Farnesal 0.85 >11.11 0 of 2 >11.11 0 of 2 13.51 – R MM Natsch et al.
(2013)
Sodium lauryl sulfate 0.77 >30 0 of 3 >30 0 of 3 >36  R M Natsch et al.
(2013)
4-Allylanisole 2.00 >540 1 of 4 540.00 1 of 4 >540 - NR MM Natsch et al.
(2013)
Hydroxycitronellal 2.03 189.04 2 of 3 424.68 1 of 3 >434 + NR ND
(continued on next page)
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Table 2 (continued)
Test substance Imax
(fold)
Concentration
(lM) for 1.5
fold induction
Number
of EC1.5
positives
Concentration
(lM) for 2 fold
induction
Number
of EC2.0
positives
Concentration
(lM) causing
50%
cytotoxicity
LuSens
prediction
Reproducibility Comparison
with
KeratinoSens™
References
Phenyl benzoate 1.14 >250 0 of 3 >250 0 of 3 >360  R M Natsch et al.
(2013)
Cinnamyl alcohol 7.28 <168.79 3 of 3 <168.79 3 of 3 >420 + R M Natsch et al.
(2013)
Imidazolidinyl urea 4.72 31.10 3 of 4 37.20 3 of 4 55.56 + NR M Natsch et al.
(2013)
Undecylenic acid 8.05 <172.36 2 of 2 <172.36 2 of 2 >428.88 + R M Natsch et al.
(2013)
Ethylene glycol
dimethacrylate
31.84 <120.56 3 of 3 <120.56 3 of 3 >300 + R M Natsch et al.
(2013)
Pyridine 1.46 >2400 0 of 4 >2400 0 of 4 >2400  R M Natsch et al.
(2013)
Aniline 1.04 >2400 0 of 2 >2400 0 of 2 >2400  R ? Natsch et al.
(2013), Bauch
et al. (2012)
Methyl methacrylate 7.33 <1205.63 2 of 2 <1205.63 2 of 2 >3000 + R ? KeratinoSens
Invittox (2010),
Bauch et al.
(2012)
4-Nitrobenzyl bromide 3.18 <0.88 3 of 3 <0.88 3 of 3 >2.18 + R M Natsch et al.
(2013)
Butyl 4-hydroxy benzoate 4.69 <22.10 3 of 3 <22.10 3 of 3 >55 + R ND
Methyl 4-hydroxy benzoate 6.70 <381.78 3 of 3 <381.78 3 of 3 >950 + R M Natsch et al.
(2013)
Sorbic acid 4.20 <964.51 3 of 3 1893.00 3 of 3 >2400 + R ND
Luperox A75 2.28 41.50 1 of 4 46.82 0 of 4 >49.8  NR ND
Butyl glycidyl ether 4.80 <72.34 3 of 3 <72.34 3 of 3 >180 + R M Natsch et al.
(2013)
Ethylparaben 3.67 <108.51 3 of 3 <108.51 3 of 3 >270 + R ND
2-Bromo-2-nitro-1,3-
propanediol
5.47 <29.18 3 of 3 38.84 3 of 3 72.10 + R ND
Xylene 1.43 >578.70 0 of 4 >578.70 0 of 4 814.45  R M Natsch et al.
(2013)
Glycerol 1.16 >2400 0 of 3 >2400 0 of 3 >2400  R M Natsch et al.
(2013)
1,2-Propanediol 1.21 >2400 0 of 2 >2400 0 of 2 >2400  R M Natsch et al.
(2013)
4-Hydroxybenzoic acid 1.06 >2400 0 of 2 >2400 0 of 2 >2400  R M Natsch et al.
(2013)
4-Methoxy acetophenone 8.97 <964.51 2 of 2 <964.51 2 of 2 >2400 + R M Natsch et al.
(2013)
6-Methylcoumarin 3.54 <120.56 3 of 3 141.48 3 of 3 >300 + R M Natsch et al.
(2013)
Chlorobenzene 1.48 >2000 0 of 4 >2000 0 of 4 1989.00  R M Natsch et al.
(2013)
DL-lactic acid 0.98 >7000 0 of 2 >7000 0 of 2 >7000  R M Natsch et al.
(2013)
Fumaric acid 1.27 >2400 0 of 3 >2400 0 of 3 >2400  R M Natsch et al.
(2013)
D(+)glucose 1.07 >3000 0 of 3 >3000 0 of 3 >3000  R M Natsch et al.
(2013)
Isopropanol 1.23 >3000 0 of 3 >3000 0 of 3 >3000  R M Natsch et al.
(2013)
Methyl salicylate 2.22 <803.76 3 of 4 1851.96 1 of 4 >2000 + NR MM Natsch et al.
(2013)
n-Butanol 1.62 2400.00 1 of 4 >2400 0 of 4 >2400  NR M
n-Hexane 1.23 >2400 0 of 3 >2400 0 of 3 >2400  R ? Natsch et al.
(2013), Bauch
et al. (2012)
Nickel chloride 0.79 >261.20 0 of 3 >261.20 0 of 3 >261.20  R ? Natsch et al.
(2013), Bauch
et al. (2012)
4-Aminobenzoic acid 1.11 >2400 0 of 2 >2400 0 of 2 >2400  R M Natsch et al.
(2013)
Propyl-4-hydroxybenzoate 3.94 <65.104 2 of 2 <65.104 2 of 2 >162 + R ND
Salicylic acid 0.80 >3000 0 of 3 >3000 0 of 3 >3000  R M Natsch et al.
(2013)
Sulfanilamide 1.08 >2400 0 of 2 >2400 0 of 2 >2400  R M Natsch et al.
(2013)
Vanillin 1.48 >1650 0 of 3 >1650 0 of 3 >1650  R M Natsch et al.
(2013)
Hexadecyltrimethylamonium
bromide
0.95 >0.69 0 of 4 >0.69 0 of 4 1.03  R ND
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Table 2 (continued)
Test substance Imax
(fold)
Concentration
(lM) for 1.5
fold induction
Number
of EC1.5
positives
Concentration
(lM) for 2 fold
induction
Number
of EC2.0
positives
Concentration
(lM) causing
50%
cytotoxicity
LuSens
prediction
Reproducibility Comparison
with
KeratinoSens™
References
Tween 80 3.76 <65.91 4 of 4 <65.91 3 of 4 >164 + R M Natsch et al.
(2013)
Diethyl phthalate 3.37 <516.41 0 of 3 516.41 0 of 3 >1285  R M Natsch et al.
(2013)
Sodium benzoate 1.01 >2400 0 of 3 >2400 0 of 3 >2400  R ND
Benzyl alcohol 1.93 <964.51 2 of 3 >2400 1 of 3 >2400 + NR ND
Table 3
Summary of predictivity of LuSens assay based on 69 test substances.
In comparison to
Human LLNA
n 69 72
Sensitivity 83% 74%
Speciﬁcity 81% 74%
PPV 88% 86%
NPV 76% 56%
Accuracy 83% 74%
T. Ramirez et al. / Toxicology in Vitro 28 (2014) 1482–1497 149392% for 63 compounds in total (for which data for both assays were
available). A concordance of 94% was reached for the 52 test com-
pounds for which human data from the literature were available
and 93% for the 61 test compounds from which LLNA data were
available. From these 52 compounds, for which human data were
available, non-concordant data (mismatch) were observed for
three substances. In the LuSens methyl salicylate (non to very
weak sensitizer in humans) tested positive, ethylenediamine (pro-
hapten) and propyl gallate (both sensitizers in humans) tested neg-
ative. The discordant results with methyl salicylate are probably
the consequence of borderline readouts in both assays. It is worth
noticing that non-concordant data are also reported for substances
tested multiple times in the same assay since some variations
within the same system are expected under the frame of technical
or biological difference (intra-laboratory variation).
In the case of the substances predicted as false negative, ethy-
lenediamine and propyl gallate both substances were rated as posi-
tive in the KeratinoSens™ assay but negative in the LuSens assay.
KeratinoSens™ only requires one single concentration of the test
substance yielding an induction higher than 1.5 fold whereas
LuSens requires at least two consecutive concentrations.
Seven substances did not yield consistent results in the data
previously published for KeratinoSens™ assay, i.e., tartaric acid,
hexane, nickel chloride, methylmethacrylate, aniline, eugenol and
a-hexyl cinnamic aldehyde (Natsch et al., 2013; Bauch et al.,
2012; KeratinoSens Invittox, 2010). The results of these substances
were therefore not used for comparisons to LuSens data (Table 2).
For 57 of the 61 compounds with available LLNA data consistent
results in both the LuSens and KeratinoSens™ resulted in 93% con-
cordance among both assays. Only four test substances did not pro-
vided concordant data among both assays, i.e., methyl salicylate,
farnesal, ethylenediamine and propyl gallate. For these substances
the LuSens assay results were consistent with the LLNA results. For
additional seven substances no comparison was possible since data
in the literature were not concordant for following substances in
the KeratinoSens™ assay: tartaric acid, n-hexane, nickel chloride,
methylmethacrylate, aniline, eugenol and a-hexyl cinnamic alde-
hyde (Natsch et al., 2013; Bauch et al., 2012; KeratinoSens
Invittox, 2010; Natsch et al., 2011, Table 2).
According to the performance standard guidance for Keratino-
Sens™, the value for similar or modiﬁed test methods is requiredto be equal to or greater than 80% based on the data of three inde-
pendent experiments for 12 reference substances (OECD 2014). In
the LuSens assay all but one substance of these 12 reference sub-
stances were reproducible (92%) and hence the criteria for the
intralaboratory reproducibility fully met and almost identical to
the overall within laboratory reproducibility described above for
the 74 compounds assessed.
3.5. LuSens assay as part of a testing strategy
The pragmatic ‘weight of evidence’ approach predicts skin sen-
sitization potential based on two of three tests addressing protein
reactivity (e.g., DPRA), keratinocyte ARE activation (e.g., LuSens)
and dendritic cell activation (e.g., h-CLAT); i.e., concordant results
of two tests then determines whether a substance is considered
to be a sensitizer or not (if at least two tests are negative the sub-
stance is assessed as a being a non-sensitizer and vice versa; Bauch
et al., 2012). When the LuSens results are used in combination with
previously reported data for DPRA and mMUSST and compared to
LLNA data, the sensitivity is 75%, speciﬁcity is 94% and the accuracy
is 81% (43 of 53 correct predictions) (Table 4). 9 Substances would
be rated as false negative: phthalic anhydride, a-hexyl cinnamic
aldehyde, tartaric acid, farnesal, SDS, pyridine, aniline, xylene and
6-methylcoumarin, whereby only nickel chloride as false positive.
Similar calculations were performed for the combination of DPRA,
LuSens and h-CLAT (data are summarized in Table 4). When com-
paring the results of this set of chemicals to human data, the LLNA
had 96% sensitivity, 81% speciﬁcity and an accuracy of 90% indicat-
ing that the LLNA also did not correctly predict the sensitization
potential for humans for all chemicals tested. When compare to
human data the combination of LuSens, DPRA and mMUSST yields,
the predictivity of the combination yields sensitivity, 82%, speciﬁc-
ity of 100% and accuracy of 92% (45 of 50 correct predictions)
(Table 4, compare to human data), Five substances would be rated
as false negative: phtalic anhydride, tartaric acid, a-hexyl cinnamic
aldehyde, undecylenic acid, and aniline.4. Discussion
Although animal tests encompass all steps leading to an adverse
reaction, they remain a ‘‘blackbox’’ as the ﬁnal reactions are mon-
itored but no knowledge is generated elucidating the pathways
leading to these effects. When developing new toxicological tests,
the current approach is therefore to understand the key steps lead-
ing to the reactions assessed by the toxicological endpoint and to
utilize this knowledge to optimize tests and test strategies. Accord-
ing to the OECD, ‘‘an adverse outcome pathway (AOP) is the
sequence of events from the chemical structure of a target chemi-
cal or group of similar chemicals through the molecular initiating
event to an in vivo outcome of interest’’. Skin sensitization is a mul-
tistep process and the key steps involved are fairly well understood
(EURL ECVAM, 2013a). The OECD recently published a document
describing adverse outcome pathway for skin sensitization
Table 4
Summary of predictivities of single assays and combinations thereof: LuSens assay and other assays (OECD QSAR toolbox, Direct Peptide Reactivity Assay (DPRA), modiﬁed
myeloid U937 skin sensitization test (mMUSST), human cell line activation test (h-CLAT). Data were obtained from Bauch et al., 2012). These ﬁgures are based on 50 test
substances (out of a total of 69) for which all data are available.
Compared to human
Sensitivity (%) Speciﬁcity (%) PPV (%) NPV (%) Accuracy (%)
LLNA 96 81 87 94 90
Single assays OECD QSAR toolbox 64 100 100 69 80
DPRA 89 82 86 86 86
LuSens 79 82 85 75 80
KeratinoSens™ 86 73 80 80 80
mMUSST 68 100 100 71 82
h-CLAT 75 77 81 71 76
Combinations DPRA and LuSens 96 64 77 93 82
DPRA and KeratinoSensTM 100 59 76 100 82
DPRA and mMUSST 93 82 87 90 88
DPRA and h-CLAT 96 59 75 93 80
LuSens and mMUSST 93 82 87 90 88
LuSens and h-CLAT 93 73 81 89 84
KeratinoSens™ and MUSST 90 56 77 77 77
KeratinoSens™ and h-CLAT 93 64 76 88 80
Prediction model (high overall accuracy) DPRA. LuSens and mMUSST 82 100 96 84 90
DPRA. KeratinoSensTM and mMUSST 86 95 96 84 90
DPRA. LuSens and h-CLAT 86 86 89 83 86
DPRA. KeratinoSensTM and h-CLAT 89 82 86 86 86
Compared to LLNA
Sensitivity (%) Speciﬁcity (%) PPV (%) NPV (%) Accuracy (%)
Single assays OECD QSAR toolbox 56 100 100 52 70
DPRA 81 76 88 65 79
LuSens 69 82 89 56 74
KeratinoSens™ 83 76 88 68 81
mMUSST 64 94 96 55 74
h-CLAT 72 76 87 57 74
Combinations DPRA and LuSens 89 59 82 71 79
DPRA and KeratinoSens™ 94 59 83 83 83
DPRA and mMUSST 86 76 89 72 83
DPRA and h-CLAT 89 53 80 69 77
LuSens and mMUSST 83 76 88 68 81
LuSens and h-CLAT 86 71 86 71 81
KeratinoSens™ and MUSST 89 71 86 75 83
KeratinoSens™ and h-CLAT 89 65 84 73 81
Prediction model DPRA, LuSens and mMUSST 75 94 96 64 81
DPRA, KeratinoSensTM and mMUSST 81 88 94 68 83
DPRA, LuSens and h-CLAT 81 88 94 68 83
DPRA, KeratinoSens™ and h-CLAT 83 82 91 70 83
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ing the development of new toxicological test methods and ITS
to assess skin sensitization (ENVJMV/MONO, 2012). Among the
steps deﬁned, protein binding, keratinocyte and dendritic cell acti-
vation are key initiating steps in the sensitization process.
In this study, a new stable ARE reporter gene assay based on a
human keratinocyte cell line, LuSens, was developed and evaluated
for its use in the identiﬁcation of skin sensitizers. The LuSens assay
provides information on both protein reactivity and keratinocyte
activation. This is accomplished by monitoring the activity of lucif-
erase, which is regulated by the ARE of the rat Nqo1 gene located
upstream the luciferase reporter gene, following contact to a test
substance. Protein reactivity of a substance can be indirectly
assessed, as reactivity with the cysteine residues of Keap1 leads
to the dissociation of Nrf2 and its subsequent binding to ARE and
the expression of the downstream genes, in this case luciferase.
As described extensively in the literature, ARE plays a crucial role
in the activation of cytoprotective genes in the elicitation of the
toxicity pathway induced by skin sensitizers (Natsch and Emter,
2008; Johnson et al., 2008) and therefore cell activation can be
assessed by the expression of luciferase. Since keratinocytes are
the ﬁrst cells exposed to a substance when skin contact occurs,the LuSens assay was designed using the primary target cells of
the skin, namely the keratinocytes, and thereby gives a measure
of their activation as cellular event leading to skin sensitization.
The validity criteria of the LuSens assay described here were
reﬁned from the initially used criteria (Bauch et al., 2012). The
assay avoids the use of concentrations inducing toxicity greater
than 30%. For this purpose, the assay includes a range ﬁnding
experiment to select the concentration range that will be used in
the main experiment and thereby avoids testing of unneeded toxic
concentrations. In addition, a rigorous prediction model was
applied, meaning that sensitizer compounds were only those that
had the capacity to induced P1.5 luciferase induction in two
consecutive test concentrations and at least half of the tested con-
centrations should have yielded a viability P70%. Substances that
induced luciferase expression only in one concentration or in non-
consecutive concentrations were considered to be non-sensitizers.
Although the validation of the assay has been designed to be
used with the SteadyGlo™ luciferase assay system to measure
luciferase activity, recent data from our laboratory with a small
set of test compounds (i.e., 8 compounds in at least 2 independent
experiments, data not shown) demonstrated the same proﬁciency
when using OneGlo™ luciferase detection system. This detection
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2007), as some detection difﬁculties can be encountered
depending on the equipment used when using the SteadyGlo™
luciferase assay (personal communication). However, in our hands,
both luciferase detection system delivered comparable data, but
the OneGlo™ system provided a stronger signal.
The LuSens assay shows good accuracy, sensitivity and speciﬁc-
ity values that are comparable to those of the KeratinoSens™ assay.
The luciferase reporter gene in the LuSens assay is under the con-
trol of the ARE-element of Nqo1 gene from the rat, which is acti-
vated by the Nrf2 pathway and is comparable to the ARE from
human AKR1C2 gene that has been cloned into KeratinoSens™
(Nioi and Hayes, 2004; Natsch and Emter, 2008). In addition,
LuSens cell-line used in this study was derived from the selected
clone which gave the best signal to noise ratio of the light output
of luciferase induction, and which showed good luciferase induc-
tion when treated with weak sensitizers. The latter is also reﬂected
in the use of the weak sensitizer EGDMA as a positive control of the
assay. Recent experiments in which the cells have been cultured in
the absence of puromycin for more than 15 cell passages exhibited
the same proﬁciency towards a small set of skin sensitizers (Fig. 3),
an indication that the inserted sequence was stably inserted into
the cells.
Based on the established validity criteria, an analysis of the pre-
dictivity of the method was conducted with a set of 74 substances
comprising 42 skin sensitizers with a wide range of potencies and
27 non-sensitizing substances comprised of various industrially
used substances and cosmetic ingredients. Human data were avail-
able for 69 substances and LLNA data was available for 72 sub-
stances. An overall accuracy of 83% was achieved when
compared to human data. Seven false negative predictions were
found indicating limited applicability for acyl transferases (3 of 7
FN predictions), prohaptens (3 of 9 FN predictions, whereby the
pro Michael acceptors, except propyl gallate, were correctly pre-
dicted), and the difﬁculty to predict nickel chloride (false negative
in the LLNA). In both the KeratinoSens™ and LuSens assays, phtha-
lic anhydride is not correctly predicted. In the DPRA, phthalic anhy-
dride exhibits virtually no cysteine binding but a strong reactivity
to lysine (Gerberick et al., 2008). As the LuSens assay assesses the
activation of the ARE dependent gene expression in keratinocytes
by modiﬁcation of a cysteine in the Nrf2 protein, some molecular
or cellular events contributing to skin sensitization may be missed.
This may, however, be balanced by using a testing battery of three
assays addressing several steps of the adverse outcome pathway
and in particular the DPRA which assesses both cysteine and lysine
reactivity.
Other limitations of the LuSens assay, as is the case with most
cell-based methods, solubility and cytotoxicity of the substance
can limit the applicability as the cells are cultured in aqueousFig. 3. Effect of increasing concentrations of the weak sensitizer, EGDMA on the
luciferase expression (bars) and viability (green squares) of LuSens cells clone 16
that have been culture without the puromycin antibiotic as selection pressure.
Illustrated are results of four independent experiments.medium. The metabolic capacity of the cells which is required to
activate certain pro-haptens is not identical to the metabolic
capacity of native skin (Götz et al., 2012; Jäckh et al., 2012;
Fabian et al., 2013).
There are limitations to any toxicological test method, and these
must be considered to reliably ensure predictions of potential haz-
ards to human health. The LLNA is the method of choice to assess
the skin sensitization potential of a substance under REACH. The
predictive accuracy of the LLNA, compared to human data was
72% (n = 74) based on the formal validation conducted by ICCVAM
(http://ntp.niehs.nih.gov/iccvam/docs/immunotox_docs/llna/llna-
rep.pdf). To date, no non-animal test method has been accepted as a
full replacement of the animal based tests for skin sensitization.
Even those currently advanced in validation process (DPRA, Kerati-
noSens™, h-CLAT) will not achieve regulatory acceptance as a
stand-alone method but they will ﬁnd use in ITSs. The combination
of these assays should be acceptable to fully replace animal testing
for the identiﬁcation of a skin sensitization potential in the near
future in particular in the context of an AOP-based IATA. In a recent
workshop with regulators (ECHA and member state representa-
tives) and industry, it was agreed that an ITS should preferably be
composed of methods which had a sound mechanistic rationale,
e.g., by reﬂecting key steps in the AOP (Basketter et al., 2013).
Two studies with large databases have demonstrated, that a combi-
nation of these or similar assays covering three key steps of the AOP
offers a high predicitivity of the skin sensitization potential (haz-
ard) even when using a simple prediction model such as ‘‘2 out of
3’’ weight of evidence approach (also sometimes termed the
‘‘majority vote’’ approach; Bauch et al., 2012; Natsch et al., 2013).
The LuSens assay (as does the KeratinoSens™ assay) contributes
to the 3R principles as it addresses one step of the adverse outcome
pathway, namely keratinocyte activation. ITSs using combinations
of the LuSens assay with other non-animal tests can result in pre-
dictivities comparable to or even higher than the LLNA. In Phase 3
of REACH an evaluation of the sensitization hazard for thousands of
substances produced at 1–100 tons will need to be submitted by
spring 2018. Bearing this in mind, the application of the LuSens
assay in a testing battery can quite conceivably signiﬁcantly con-
tribute to the reduction of the number of animals used for REACH.
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